Re-Vana Therapeutics
BPharm (Hons)
Previous Company: University of Strathclyde
Thakur Raghu Raj Singh is the Co-Founder, CTO & Director at Re-Vana Therapeutics. Thakur was previously a Senior Lecturer in Pharmaceutics at Queen's University Belfast from August 2017 to July 2019. From August 2010 to July 2017 they were a Lecturer in Pharmaceutics at Queen's University Belfast. From October 2009 to July 2010 they were a Research Assistant at Queen's University Belfast. Thakur received their PhD from Queen's University Belfast in September 2006 to October 2009 and their BPharm (Hons) from the University of Strathclyde.
Thakur Raghu Raj Singh has a PGCHET from Queens University Belfast in Higher Education/Higher Education Administration. Thakur also has a PhD in Drug Delivery from Queen's University Belfast. Additionally, they have an MSc in Pharmaceutical Technology from Universiti Sains Malaysia and a B.Pharm from Jawaharlal Nehru Technological University. Thakur also has a certification in PGCHET from an unspecified institution.
Some of their coworkers include Yujing Wang - Research Fellow, David T. Shima - VP of R&D, and Mike Nash - Chief Commercial Officer. Their manager is Michael O’rourke, CEO & Director.
Re-Vana Therapeutics
Re-Vana Therapeutics is an ocular pharmaceutical and drug delivery company focused on the development and commercialisation of revolutionary long-acting biodegradable drug delivery platforms to treat chronic eye diseases such as age-related macular degeneration, diabetic retinopathy, glaucoma and ocular infections.